Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the jannah domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/vhosts/pharmaleaders.com/httpdocs/wp-includes/functions.php on line 6114

Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the jannah domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/vhosts/pharmaleaders.com/httpdocs/wp-includes/functions.php on line 6114
Diabetes, weight loss drugs drive growth for Novo and Lilly despite shortages – PharmaLeaders

Patients Pharma News

Diabetes, weight loss drugs drive growth for Novo and Lilly despite shortages

Jim Walker November 10, 2023

657 Less than a minute

Novo Nordisk (NVO) and Eli Lilly (LLY) stocks were both boosted by sales of their Type 2 diabetes and weight loss drugs in the third quarter, despite shortages of supply of the three popular products — Novo’s Type 2 diabetes drug Ozempic, its weight loss drug Wegovy, and Lilly’s Type 2 drug Mounjaro — the companies announced Thursday.

The three drugs have seen a spike in popularity this year due to the unprecedented total body weight loss they provide compared to older GLP-1s — drugs that mimic a hormone in the body that slows digestion and promotes insulin production.

Continue reading @ Yahoo Finance…

Jim Walker November 10, 2023

657 Less than a minute

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.